Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development and commercialisation of products for cancer and other severe, immune, inflammatory conditions. Celgene employs more than 5,300 employees worldwide.
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer.
SERVIER is the first independent French pharmaceutical company established in more than 140 countries. Nearly 3000 researchers are preparing the drugs of the future. SERVIER is strongly committed to innovative research with one of the world's highest ratios of R&D investment: 27% of turnover. SERVIER is partnering with state-of-the-art research centers. Its guiding principle is to engage in cutting-edge research in cancer, and make innovative therapies available. SERVIER is conducting its research program around 3 main axes: tyrosine kinase inhibitors, inducers of apoptosis, and immunotherapies combining small molecules, engineered monoclonal antibodies, and cell therapy.